The ER signaling pathway promotes tumor progression and the cross-talk between such ER signaling pathway and cell cycle regulation, conducted by lncRNA MAFG-AS1 via MAFG-AS1/miR-339-5p/CDK2 axis, has also been identified in ER+ breast cancer cells, possibly promoting tamoxifen resistance [101]. This evidence concerns the gene ESR1 and breast carcinoma.